Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03799562 · ClinicalTrials.gov registry record · Phase 2

Neurosteroids for PTSD in Veterans

A Phase 2 study, sponsored by VA Office of Research and Development.

Completed
Registry status
Phase 2
Development phase
96
Enrollment target

NCT03799562: Completed Phase 2 study, sponsored by VA Office of Research and Development.

NCT03799562 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 96 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03799562, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.

COMPLETED
Registry status
Phase 2
Development phase
96 participants
Enrollment target

Study Summary

This study seeks to determine if pregnenolone can improve symptoms of PTSD and other symptoms that commonly occur with PTSD in Iraq/Afghanistan-era Veterans. The total study duration is 10 weeks. Eligible Veterans with PTSD will receive either pregnenolone or placebo throughout the study duration and will complete mental and physical health assessments at each study visit. Eligible participants will attend 6 in-person study visits and receive several short "check-in" phone calls.

Interventions

  • DRUG Placebo
  • DRUG Pregnenolone

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2019-05-01
Est. Completion 2025-07-14
Phase Phase 2

Sponsor

VA Office of Research and Development

1,668 total trials

What the Registry Record Tells You About NCT03799562

The ClinicalTrials.gov registry entry for NCT03799562 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT03799562 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03799562 about?

NCT03799562 is a clinical study titled "Neurosteroids for PTSD in Veterans". This study seeks to determine if pregnenolone can improve symptoms of PTSD and other symptoms that commonly occur with PTSD in Iraq/Afghanistan-era Veterans. The total study duration is 10 weeks. Eligible Veterans with PTSD will receive either pregnenolone or placebo throughout the study duration an...

What is the current status of trial NCT03799562?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2019-05-01. Estimated completion is 2025-07-14.

What interventions are being tested in trial NCT03799562?

The interventions under investigation include: Placebo (DRUG), Pregnenolone (DRUG).

Who is sponsoring clinical trial NCT03799562?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.